Scarica l'app Stockscreener
2.55
1.59%
0.04
Dopo l'orario di chiusura:
2.57
0.02
+0.78%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$2.51
Aprire:
$2.45
Volume 24 ore:
13.68M
Relative Volume:
1.70
Capitalizzazione di mercato:
$694.95M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-2.0079
EPS:
-1.27
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
+23.79%
1M Prestazione:
+48.26%
6M Prestazione:
+39.34%
1 anno Prestazione:
-64.68%
Intervallo 1D:
$2.405
$2.65
Intervallo di 1 settimana:
$2.015
$2.65
Portata 52W:
$1.16
$10.65
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Vanguard Group Inc's Strategic Reduction in Pacific Biosciences of California Inc - GuruFocus.com
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Assenagon Asset Management S.A. Trims Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Thursday - MarketBeat
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology - Insider Monkey
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep - Quantisnow
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.7%Should You Buy? - MarketBeat
PacBio unveils new sequencing chemistry to cut costs By Investing.com - Investing.com Canada
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 - Quantisnow
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a favorite amongst institutional investors who own 86% - Yahoo Finance
PACB (Pacific Biosciences of California) Cash-to-Debt : 0.55 (As of Jun. 2024) - GuruFocus.com
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program - StockTitan
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research - MSN
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 4.8%Here's Why - MarketBeat
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt? - Simply Wall St
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $4.50 - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownHere's Why - MarketBeat
Dimensional Fund Advisors LP Sells 2,121,331 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PacBio inks cancer research deal with Singapore's NCCS By Investing.com - Investing.com South Africa
PacBio inks cancer research deal with Singapore's NCCS - Investing.com India
Pacific Biosciences of California (NASDAQ:PACB) Trading 18.4% HigherHere's Why - MarketBeat
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing - StockTitan
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire
Squarepoint Ops LLC Purchases Shares of 524,608 Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Marshall Wace LLP Raises Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) - MSN
PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore - StockTitan
PacBio's SWOT analysis: genomics firm faces headwinds, seeks growth - Investing.com
PacBio Grants Equity Incentive Award to New Employee - Quantisnow
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Oracle Investment Management Inc. - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down to $2.04 - MarketBeat
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $4.50 Average Price Target from Analysts - MarketBeat
RNA sequencing with Kinnex kits transforms University of Southampton rare disease research - Pacific Biosciences
A stock that deserves closer examination: Pacira BioSciences Inc (PCRX) - US Post News
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.87 - MarketBeat
Stocks of Pacific Biosciences of California Inc (PACB) are poised to climb above their peers - SETE News
Riding the Waves: A Guide to Investing in PCRX Stock - The InvestChronicle
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.7% - Defense World
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Guess which ASX biotech stock is surging 11% on big FDA news - The Motley Fool Australia
Analysts review Pacira BioSciences Inc’s rating - Knox Daily
The time has not yet come to remove your chips from the table: PACS Group Inc. (PACS) - SETE News
Insider’s View: Deciphering Pacira BioSciences Inc (PCRX)’s Financial Health Through Ratios - The Dwinnex
Pacific Biosciences of California Inc’s Mixed Bag: Down -51.19% in 6 Months, Down 9.47% in 30 Days - The InvestChronicle
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Purchased by Daiwa Securities Group Inc. - Defense World
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):